666 related articles for article (PubMed ID: 26240135)
41. Clinical Utility of Routine Cardiac Monitoring in Breast Cancer Patients Receiving Trastuzumab.
Davis CC; Zelnak A; Eley JW; Goldstein DA; Switchenko JM; McKibbin T
Ann Pharmacother; 2016 Sep; 50(9):712-7. PubMed ID: 27307412
[TBL] [Abstract][Full Text] [Related]
42. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study.
Pivot X; Suter T; Nabholtz JM; Pierga JY; Espie M; Lortholary A; Khayat D; Pauporte I; Romieu G; Kramar A; Fumoleau P
Eur J Cancer; 2015 Sep; 51(13):1660-6. PubMed ID: 26163096
[TBL] [Abstract][Full Text] [Related]
43. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
Cao L; Cai G; Chang C; Yang ZZ; Feng Y; Yu XL; Ma JL; Wu J; Guo XM; Chen JY
Oncotarget; 2016 Jan; 7(1):1042-54. PubMed ID: 26460956
[TBL] [Abstract][Full Text] [Related]
44. Reliability of Left Ventricular Ejection Fraction from Three-Dimensional Echocardiography for Cardiotoxicity Onset Detection in Patients with Breast Cancer.
Lorenzini C; Lamberti C; Aquilina M; Rocca A; Cortesi P; Corsi C
J Am Soc Echocardiogr; 2017 Nov; 30(11):1103-1110. PubMed ID: 28822666
[TBL] [Abstract][Full Text] [Related]
45. Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy.
Huang P; Dai S; Ye Z; Liu Y; Chen Z; Zheng Y; Shao X; Lei L; Wang X
Oncotarget; 2017 Jan; 8(2):2069-2075. PubMed ID: 27906683
[TBL] [Abstract][Full Text] [Related]
46. Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients.
Dores H; Abecasis J; Correia MJ; Gândara F; Fonseca C; Azevedo J; Arroja I; Martins A; Mendes M
Arq Bras Cardiol; 2013 Apr; 100(4):328-32. PubMed ID: 23525273
[TBL] [Abstract][Full Text] [Related]
47. Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Venturini M; Bighin C; Monfardini S; Cappuzzo F; Olmeo N; Durando A; Puglisi F; Nicoletto O; Lambiase A; Del Mastro L
Breast Cancer Res Treat; 2006 Jan; 95(1):45-53. PubMed ID: 16267615
[TBL] [Abstract][Full Text] [Related]
48. Cardiotoxicity of novel HER2-targeted therapies.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2013 Aug; 29(8):1015-24. PubMed ID: 23692263
[TBL] [Abstract][Full Text] [Related]
49. Prolonged electromechanical delay as an early predictor of trastuzumab-induced cardiotoxicity in patients undergoing treatment for breast cancer.
Choe JC; Choi JH; Choi JH; Ahn J; Park JS; Lee HW; Oh JH; Lee HC; Cha KS; Hong TJ
Clin Cardiol; 2018 Oct; 41(10):1308-1314. PubMed ID: 30239009
[TBL] [Abstract][Full Text] [Related]
50. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
[TBL] [Abstract][Full Text] [Related]
51. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
[TBL] [Abstract][Full Text] [Related]
52. Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
Bergamini C; Niro L; Springhetti P; Ferri L; Trento L; Minnucci I; Maffeis C; Tafciu E; Rossi A; Fiorio E; Benfari G; Ribichini F
Cardiovasc Toxicol; 2024 Jun; 24(6):550-562. PubMed ID: 38696070
[TBL] [Abstract][Full Text] [Related]
53. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
54. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
[TBL] [Abstract][Full Text] [Related]
55. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study.
Gunaldi M; Duman BB; Afsar CU; Paydas S; Erkisi M; Kara IO; Sahin B
J Oncol Pharm Pract; 2016 Apr; 22(2):242-7. PubMed ID: 25567518
[TBL] [Abstract][Full Text] [Related]
56. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study.
Lynce F; Barac A; Geng X; Dang C; Yu AF; Smith KL; Gallagher C; Pohlmann PR; Nunes R; Herbolsheimer P; Warren R; Srichai MB; Hofmeyer M; Cunningham A; Timothee P; Asch FM; Shajahan-Haq A; Tan MT; Isaacs C; Swain SM
Breast Cancer Res Treat; 2019 Jun; 175(3):595-603. PubMed ID: 30852761
[TBL] [Abstract][Full Text] [Related]
57. Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population.
Baron KB; Brown JR; Heiss BL; Marshall J; Tait N; Tkaczuk KH; Gottlieb SS
J Card Fail; 2014 Aug; 20(8):555-9. PubMed ID: 24905295
[TBL] [Abstract][Full Text] [Related]
58. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
[TBL] [Abstract][Full Text] [Related]
59. Cardioprotective Effect of Statins in Patients With HER2-Positive Breast Cancer Receiving Trastuzumab Therapy.
Calvillo-Argüelles O; Abdel-Qadir H; Michalowska M; Billia F; Suntheralingam S; Amir E; Thavendiranathan P
Can J Cardiol; 2019 Feb; 35(2):153-159. PubMed ID: 30760421
[TBL] [Abstract][Full Text] [Related]
60. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.
Cardinale D; Colombo A; Torrisi R; Sandri MT; Civelli M; Salvatici M; Lamantia G; Colombo N; Cortinovis S; Dessanai MA; Nolè F; Veglia F; Cipolla CM
J Clin Oncol; 2010 Sep; 28(25):3910-6. PubMed ID: 20679614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
